Skip to content
Biodatica
Start free

Incyte Corporation

Phoenix, Arizona

OncologyPhase IListed · INCY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Sign in to watch

What changed

Phase I trial registered: Study of INCA036978 in Participants With Myeloproliferative Neoplasms

7w agoTrial registeredMay 29, 2026Source filing (opens the source filing in a new tab)

Momentum

85no change

Momentum 85 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    May 11, 2026

    Myeloproliferative Neoplasms · RECRUITING · sponsor: Incyte Corporation · Study of INCA036978 in Participants With Myeloproliferative Neoplasms

    ClinicalTrials.gov · NCT07441694 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Mar 27, 2025

    Solid Tumors · ACTIVE_NOT_RECRUITING · sponsor: Incyte Corporation · A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

    ClinicalTrials.gov · NCT06818812 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Jan 4, 2024

    Solid Tumors · RECRUITING · sponsor: Incyte Corporation · A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

    ClinicalTrials.gov · NCT06179160 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources